Recent Updates
Recently added Catalysts

Castration-Resistant Metastatic Prostate Cancer: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.2Buniverse median $1.20B
Allocated capital$613M$1.2B competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank189/299crowding rank 199

Castration-Resistant Metastatic Prostate Cancer is uncontested. Monte Rosa Therapeutics (GLUE) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with MRT-2359 in phase 2.

There is no public comparable to price it against. GLUE spreads its $1.2B market cap across 2 indications, so $613M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$613M of allocated capital sits in Castration-Resistant Metastatic Prostate Cancer, ranking it 189th of 299 indications by the money committed to it.

Companies developing drugs for Castration-Resistant Metastatic Prostate Cancer 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
GLUEMonte Rosa TherapeuticsMRT-2359Phase 22$1.2BNo2 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Castration-Resistant Metastatic Prostate Cancer counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Castration-Resistant Metastatic Prostate Cancer has one competitor and a median of $1.2B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Relapsed or Refractory Non-Hodgkin's Lymphoma1 company · $601M · median $601MUncontestedAdvanced Cutaneous Melanoma1 company · $634M · median $1.3BUncontestedMyelodysplastic Syndromes2 companies · $572M · median $1.5BConcentrated betMalignant Melanoma1 company · $657M · median $3.9BUncontestedUnresectable Melanoma1 company · $657M · median $3.9BUncontestedNon-Muscle Invasive Bladder Cancer (NMIBC)1 company · $723M · median $8.7BUncontestedRefractory Non-Hodgkin's Lymphoma1 company · $723M · median $8.7BUncontestedHPV-Related Carcinoma1 company · $723M · median $8.7BUncontested

Castration-Resistant Metastatic Prostate Cancer pipeline questions

Which biotech companies are developing drugs for Castration-Resistant Metastatic Prostate Cancer?

Monte Rosa Therapeutics (GLUE, MRT-2359, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Castration-Resistant Metastatic Prostate Cancer.

How advanced is the Castration-Resistant Metastatic Prostate Cancer pipeline?

Of the 1 clinical-stage programme in Castration-Resistant Metastatic Prostate Cancer, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Castration-Resistant Metastatic Prostate Cancer?

No. GLUE is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Castration-Resistant Metastatic Prostate Cancer, which is why the indication is classified as uncontested.

When is the next Castration-Resistant Metastatic Prostate Cancer catalyst?

The next dated catalyst in Castration-Resistant Metastatic Prostate Cancer is GLUE on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map